Optimization of an immunotherapeutic protocol with poly(I,C)-LC.
The development of successful immunotherapeutic protocols requires new therapeutic strategies as well as the development of clinically predictive tumor models and protocols. A bell-shaped response curve is observed with many biological response modifiers (BRMs), not only for immunomodulation, but also for therapeutic activity. Although most BRMs, including poly(I,C)-LC, are toxic at high doses, the administration of nontoxic doses by an optimal protocol and route of injection results in significant therapeutic benefit and increased immunomodulation in tumor-bearing animals compared to the administration of a maximum tolerated dose (MTD). We suggest that Phase II clinical trials using an optimal immunomodulatory protocol may result in increased therapeutic activity compared to protocols based on the MTD.
D000818:Animals; D002266:Carboxymethylcellulose Sodium / Q000008:administration & dosage / Q000627:therapeutic use* / Q000031:analogs & derivatives; D002460:Cell Line; D004334:Drug Administration Schedule; D007167:Immunotherapy; D007369:Interferon Inducers / Q000627:therapeutic use*; D008747:Methylcellulose / Q000031:analogs & derivatives*; D051379:Mice; D009362:Neoplasm Metastasis; D009374:Neoplasms, Experimental / Q000628:therapy*; D011070:Poly I-C / Q000008:administration & dosage / Q000627:therapeutic use*; D011107:Polylysine / Q000008:administration & dosage / Q000627:therapeutic use* / Q000031:analogs & derivatives
D007369:Interferon Inducers; D011107:Polylysine; C019531:poly ICLC; D008747:Methylcellulose; D002266:Carboxymethylcellulose Sodium; D011070:Poly I-C